Indeed, treatment of mice suffering from aggressive lung cancer in vivo with the ETP-47037 PI3K/TRF1 inhibitor developed by us significantly decreased telomere TRF1 foci, induced telomeric DNA damage and blocked tumor growth as compared to non-treated mice39. This evidence concerns the gene PIK3CA and neoplasm.